{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-013290","form_type":"8-K","ticker":"ENVB","cik":"0000890821","company_name":"Enveric Biosciences, Inc.","filed_at":"2026-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.963760+00:00","generated_at":"2026-05-15T08:45:56.704221+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Enveric Biosciences reports Q4 2025 net loss of $4.0M, cash $4.7M, advances EB-003 towards IND","bullets":["Net loss of $4.0M in Q4 2025 ($6.12 per share) vs $3.2M loss ($58.06 per share) in Q4 2024; per-share impacted by 1:12 reverse split.","Cash $4.7M at Dec 31; raised $12.2M in gross proceeds during FY 2025; subsequently raised $1.5M (Jan 2026) and $1.45M (Feb 2026).","EB-003 showed positive preclinical results in chronic depression and PTSD models; preparing IND submission to FDA for first-in-human trial.","PGR petition by Gilgamesh/AbbVie against Enveric patent withdrawn; patent covers bretisilocin (GM-2505) acquired by AbbVie for $1.2B."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-013290","json":"https://secwatch.observer/filing/0001493152-26-013290.json","markdown":"https://secwatch.observer/filing/0001493152-26-013290.md","text":"https://secwatch.observer/filing/0001493152-26-013290.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/890821/000149315226013290/0001493152-26-013290-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/890821/000149315226013290/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:45:56.704221+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"745f50f3001286e02d1be0539e4d848cd66e4741","claim":"Enveric Biosciences, Inc. reported financial results for the fourth quarter and year ended December 31, 2025.","evidence_excerpt":"Enveric Biosciences, Inc. issued a press release providing a corporate update and announcing its financial results for the fourth quarter and year ended December 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/890821/000149315226013290/0001493152-26-013290-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}